Compare ISSC & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ISSC | SABS |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.7M | 336.6M |
| IPO Year | 2000 | 2020 |
| Metric | ISSC | SABS |
|---|---|---|
| Price | $24.78 | $3.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $18.25 | $10.75 |
| AVG Volume (30 Days) | 280.7K | ★ 359.8K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 78.53 |
| EPS | ★ 0.66 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.95 | N/A |
| Revenue Next Year | $6.82 | N/A |
| P/E Ratio | $37.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.13 | $1.85 |
| 52 Week High | $30.98 | $5.15 |
| Indicator | ISSC | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 76.95 | 56.39 |
| Support Level | $17.46 | $3.64 |
| Resistance Level | $26.30 | $4.03 |
| Average True Range (ATR) | 1.38 | 0.13 |
| MACD | 0.46 | 0.01 |
| Stochastic Oscillator | 94.79 | 72.37 |
Innovative Solutions and Support Inc is a systems integrator that designs, manufactures, sells, and services air data equipment, engine display systems, standby equipment, primary flight guidance, and cockpit display systems for retrofit applications and original equipment manufacturers. The company supplies integrated Flight Management Systems, Flat Panel Display Systems, Integrated Standby Units, Positioning System receivers that enable reduced carbon footprint navigation, and an Autothrottle, which allows a pilot to automatically control the power setting of the engine and is designed to reduce pilot workload and enhance safety. It sells its products to both the OEM and the retrofit markets.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.